Keeping a form of white cells called B-cells below a count of 64 has been found to significantly reduce the number of lesions on the MRI in multiple sclerosis patients. Results show a reduction of 16 new lesions per year to just one. It does have a list of side effects and is another injectable treatment plan. Though the cancer medication used to reduce the B cells, Ofatumumab or Arzerra, is not available for MS today, it could be used in future trials. This anti-B cell study with such astounding results was completed by GlaxoSmithKline in Uxbridge, United Kingdom. 

To learn more about this topic read ScienceDaily at: http://www.sciencedaily.com/releases/2014/04/140424161527.htm. Image from: http://www.arzerra.com.